

PUBLIC HEALTH SERVICE SPECIFICATION

The service specification is a document that quantifies the minimum acceptable (technical) standard of service required by the customer and will form a part of the contract with the service provider. The production of the service specification is a pre-requisite in the negotiation and drafting of the contract. This document is to be completed by the lead commissioner prior to consultation with the relevant service providers.

Contract No & Service Name	Pharmacy Emergency Hormonal Contraception Service ; Levonorgestrel Only
Programme Area	Sexual Health
Commissioner Lead	Lee Girvan
Provider Lead	Community Pharmacies
Period	1st April 2022 – 31st March 2023
Contract Value	See section 9
Notice Period	6 Months

1. Purpose

1.1 General Overview

This specification sets out a model for the provision of an Emergency Hormonal Contraception (EHC) service involving the supply of Levonorgestrel where appropriate, by a suitably qualified and competent community pharmacist, free of charge, (funded by the commissioner), to the service user, according to the approved Patient Group Direction (PGD) for the supply of emergency hormonal contraception by a community pharmacist from a community pharmacy.

1.2 Aims

- To improve access to Emergency Hormonal Contraception (EHC) and sexual health advice.
- To increase knowledge of EHC and mainstream contraception amongst service users and healthcare professionals.
- To increase knowledge of risks associated with sexually transmitted infections (STI's) and refer to appropriate services.
- To help contribute to a reduction in the rate of unplanned pregnancies, particularly in under 18s.
- To signpost hard to reach females, especially young females, into mainstream sexual health services.
- To enhance pharmacists' professional practice.
- To enable participating pharmacists to be active participants in an integrated multi-disciplinary service to help ensure easy and swift access to advice.

1.3 Objectives

- Delivery of a user friendly, non-judgemental, client centred and confidential EHC service from community pharmacies
- Pharmacists will link into the local network of contraceptive and sexual health services to help ensure easy and swift access to advice

1.4 Expected Outcomes Including Improving Prevention

- Reduction in the under 18 conception rate.
- Reduction in the number of all age terminations of unplanned pregnancies.

1.5 Evidence Base

Recent policy

It is expected that as part of the pharmacists professional responsibility, that they are cognisant of and compliant with the latest policy guidance and clinical practice, these currently include the following;

- FSRH Emergency Contraception March 2017
- <u>Sexual Health Framework (</u>DoH Mar 2013)
- <u>Commissioning local HIV sexual and reproductive health services GOV.UK (www.gov.uk)</u>
- Faculty of Sexual and Reproductive Health Clinical Guidance
- <u>http://www.fsrh.org/standards-and-guidance//documents/fsrhqualitystandardcontraceptiveservices/</u> (April 2014)

Public Health England's 'Pharmacy: A Way Forward for Public Health' <u>Pharmacy: a way forward for public health</u> (publishing.service.gov.uk) sets out opportunities for commissioner and provider led action at a local level to realise community pharmacy's key role in enabling a healthier nation. Community pharmacy teams play a pivotal role as a community and health asset in communities. High quality public health and clinical interventions drive delivery that is focused on prevention, health improvement and protection of local communities. Pharmacy plays a vital role in the access and provision of Sexual Health, Reproductive Health & HIV services across England as part of a multi-disciplinary setting offering services.

The topic area of Sexual Health, Reproductive Health & HIV continues to face many challenges. Pharmacy teams are well placed to help provide preventative solutions to some of the topics key issues, these include unplanned pregnancies associated with poorer health and social outcomes for both mother and child.

2. Scope

2.1 Service Description

Pharmacists will supply Levonorgestrel Emergency Hormonal Contraception (EHC) when appropriate to clients in line with the requirements of a locally agreed Patient Group Direction (PGD). The PGD will specify the age range of clients that are eligible for the service; it may facilitate supply to young persons under 16 in appropriate circumstances.

This service is available to all females, irrespective of age or residency. It must be recorded whether they are a Blackburn with Darwen resident or not and appropriate advice given regarding follow up in their local area.

Clients excluded from the PGD criteria will be referred as soon as possible, to another local service that will be able to assist them, e.g. GP, community contraception service (the pharmacist must be certain that the service they refer a client to is open and accessible, by ringing ahead if necessary); or will be invited to purchase over-the-counter EHC from the pharmacy if the exclusion from supply via the PGD is only due to an administrative matter, i.e. age range determined by the Commissioner.

The pharmacy will ensure they have available, accessible and up-to-date information to enable them to signpost people to other relevant sexual health services, as required, so as to be an active participant in an integrated multi-disciplinary sexual health economy.

The contact details for the Blackburn with Darwen Integrated Sexual Health Service:

01254 268700 or visit: https://www.brook.org.uk/regions/brook-blackburn/

Pharmacists may need to share relevant information (e.g. for referrals) with other health care professionals and agencies, in line with locally determined confidentiality arrangements, including, where appropriate, the need for the permission of the client to share the information.

As part of the EHC consultation, the provider will offer/provide Chlamydia screening postal kits where appropriate to people aged 15-24 (the Pharmacist may use professional discretion for those at high risk outside this age group accessing this service). The service will be free of charge to eligible service users and is funded by the Commissioner - service users are at liberty to refuse this service. A free of charge supply of six condoms should be offered at all consultations. The provider will be able to access postal sampling kits from Sexual Health Services in their area as listed in section 2.4 Chlamydia Screening.

2.2 Accessibility, fairness and equity of provision

The pharmacy must maintain appropriate records to ensure effective ongoing service delivery and audit. Records will be confidential and should be stored securely and for a length of time in line with local NHS record retention policies.

- The commissioning of this service will reflect The Public Services (Social Value) Act 2012. Blackburn with Darwen Borough Council support this Act and will not seek just to assess the implications of commissioning decisions regarding the risk to groups of people but will look for opportunities (social value) to advance opportunities to those people.
- The service will be non-stigmatising and non-discriminatory, providing fair and equitable access. The service will comply with the Equality Act 2010.
- The service will work in a way that it does not discriminate against individuals on the grounds of gender, race, disability, sexual orientation, sexual practices, gender reassignment, age, pregnancy or maternity, marriage/civil partnership or belief system and will ensure that all applicable legislation is adhered to.
- The service is accessible to people who have had difficulties accessing support to become well, including people with mental health problems, from black and minority ethnic communities, people with sensory impairments, and people with learning disabilities or learning difficulties and people from the Gypsy / Romany / travelling communities.
- The service will meet the needs of those in training, education and employment.

2.3 Essential links to other services/ care pathways

The service will ensure links to:-

- General Practice (s)
- Chlamydia Screening Programme
- Interpreter Services
- Sexual Health Services
- Social Care
- Safeguarding Teams

2.4 Interdependency with other contracts

Pharmacies will be able to access postal chlamydia screening kits from Sexual Health Services.

Pharmacies will be required to work alongside Sexual Health Services, GP Practices and other Public Sector bodies such as the Police, Probation; and also private and third sector organisations when required. See appendix 1 for details of sexual health service providers in Blackburn with Darwen.

3.1 Service model

The pharmacy contractor must:

- Ensure that all pharmacists providing this service have completed the appropriate 'Declaration of Competence'.
- A standard operating procedure (SOP) must be produced by the service provider and reviewed annually for the provision of this service.

NOTE: The participating accredited pharmacy should only offer to sell over-the-counter EHC products when other routes of supply are not possible. Pharmacies who do not have a trained pharmacist on site to offer free EHC should signpost to a pharmacist who can and ring ahead to confirmed they are available.

3.1.1 Display

All participating accredited pharmacies will be required to provide clearly visible dedicated window space for a logo/poster indicating the availability of EHC through a pharmacy enhanced service. Posters are available to download in PDF format: <u>http://psnc.org.uk/wp-content/uploads/2013/08/ThinkPharmacyPosters.pdf</u> Family Planning leaflets are available to download in PDF format; <u>http://www.fpa.org.uk/resources/downloads</u>

3.1.2 Consultations

- The pharmacy will offer a user-friendly, non-judgmental, client-centred and confidential service.
- EHC consultations are only to be handled by qualified pharmacists who have declared competence to deliver EHC services (see 3.1). No part of the consultation may be undertaken by any other individual, although other pharmacists and pre-registration students may, with the service user's consent, observe for training purposes.
- It should be reinforced at the start of every consultation that the service is completely confidential (the only exception being when the accredited pharmacist judges that the client is at risk and involvement of others is necessary, e.g. child protection / vulnerable adults – more information to support this can be found below and on the patient assessment/consultation form).
- An assessment/consultation form must be completed for every consultation on PharmOutcomes.
- An assessment/consultation to establish the need and suitability for a client to receive EHC must be undertaken in line with the approved PGD for the supply of EHC by a community pharmacist from a community pharmacy. Where appropriate a supply will be made; where a supply of EHC is not appropriate, advice and referral to another source of assistance, if appropriate, will be provided (see also section **3.2.3**). See appendix 1 for Sexual Health Service Providers.
- The Pharmacy will perform a pregnancy test if required, as outlined in the PGD and subject to the pharmacy having suitable facilities. If a pregnancy test cannot be carried out on site the client can undertake a pregnancy test at locally identified toilet facilities and return to the pharmacy to verify and interpret the result, provided the patient returns within 72 hours of unprotected sexual intercourse.
- The service will be provided in line with 'Fraser guidelines' and 'Department of Health' guidance on confidential sexual health advice and treatment for young people aged under 16 (see 'Fraser Competence and Confidentiality' on page 1 of the 'Patient Assessment Form' in appendix 2).
- The service will be provided in accordance with national and local child and vulnerable adult protection guidelines (appendix 3 and 4).
- Supply <u>and</u> supervised consumption of EHC is a requirement of the PGD and there can be no reasonable objections, including fasting during Ramadan, from a genuine service user. If a client feels sick, they must be advised to have a snack and return shortly.

- A postal Chlamydia Screening Kit should be supplied to clients and their partners if under 25 years of age (or deemed as high risk by the pharmacist). Chlamydia Screening Kits are available through the local sexual health service (see appendix 1). Young people (aged 16 & over) can also be signposted to SH:24 (<u>https://www.brook.org.uk/regions/brook-blackburn/</u>) as one of the Public Health England appointed suppliers to the National Framework for e-Sexual and Reproductive Healthcare <u>National framework for e-sexual and reproductive healthcare: user guide, issue 2 (publishing.service.gov.uk)</u>
- The pharmacy will provide support and advice to clients accessing the service, including advice on avoidance of pregnancy and sexually transmitted infections (STIs) through safer sex and condom use i.e.
 - advice and signposting to services that provide long-term contraceptive methods
 - > advice and signposting on the use of regular contraceptive methods
 - > onward signposting to services that provide diagnosis and management of STIs.
- To support verbal advice the following should also be provided by the pharmacist;
 - Discrete supply of six regular condoms in a pharmacy bag
 - Discrete supply of appropriate leaflets available from the Family Planning Association on <u>http://www.fpa.org.uk/resources/downloads</u> to include:
 - Long acting reversible contraception methods/other methods of contraception
 - Sexually transmitted infections

3.1.3 Referral

Regardless of whether a supply is made, all clients should be advised to consult their GP, Sexual Health Services or other local services available regarding future contraceptive and/or sexual health needs. All these services are completely confidential.

3.2 Competencies and Training

The service will ensure all staff are appropriately qualified and supported in their work so as to realise their potential, work positively with service users, partners and their carers and positively promote the service.

All staff will be supported to continuously update skills and techniques relevant to their work.

Where appropriate qualified staff must be registered with a professional body e.g. The General Pharmaceutical Council (GPhC).

Staffing and management structures will be streamlined and efficient with all staff having clear areas of responsibility and remits.

A pharmacist who wishes to deliver this service must complete the CPPE and Health Education North West (NHS) 'Declaration of Competence' and by doing so declare themselves professional, confident and competent to deliver the service. To be available if requested by the commissioner.

The pharmacist must:

- Have evidence of Continuous Personal Development (CPD).
- Sign and access training during the contract period on the approved Patient Group Direction (PGD) for the supply of emergency hormonal contraception by a community pharmacist from a community pharmacy, and agree to work in accordance with the PGD.
- Provide the CPPE (or equivalent) 'Declaration of Competence' (EHC) documentation. Records of assessment for all the programmes must be retained by the pharmacy contractor, together with the EHC PGD which has been signed by all pharmacists working to the PGD, and also by the authorising manager ('Individual Authorisation' on last page of the PGD). Please click on the link to access the CPPE 'Declaration of Competence': <u>https://www.cppe.ac.uk/services/declaration-of-competence</u>
- Have appropriate indemnity insurance to provide this service.
- Reassessment of competence to deliver the EHC service is recommended at least every 3 years. Undertake disclosure and Barring <u>https://www.gov.uk/disclosure-barring-service-check/tracking-application-getting-certificate</u>

The pharmacy contractor has a duty to ensure that pharmacists and staff involved in the provision of the service have relevant knowledge and are appropriately trained in the operation of the service, including sensitive, client centred communication skills. This may be facilitated by the provision of local training.

All training costs will be met by the pharmacy/ contractor providing the EHC service.

Where interruption of the service is unavoidable, the identified pharmacist(s) will ensure that support staff and any replacement pharmacists are aware of the details of the scheme and are able to correctly signpost women to another participating pharmacy or health care provider. This will include phoning ahead, if signposting to another authorised pharmacy, to ensure that the service is available at that time. Instances must be reported to the commissioner and will be monitored. If this occurs repeatedly, the contract will be reviewed and may be terminated.

3.3 Governance

The service provider is responsible for the governance and oversight of the service being provided and should have arrangements in place to demonstrate this.

3.4 Insurance

The Provider shall at its own cost effect and maintain with a reputable insurance company a policy or policies of insurance providing the following levels of cover:

- public liability insurance with a limit of indemnity of not less than £5,000,000 in relation to any one claim or series of claims;
- employer's liability insurance with a limit of indemnity of not less than £10,000,000
- professional indemnity insurance with a limit of indemnity of not less than £2,000,000 in relation to any one claim or series
 of claims and shall ensure that all professional consultants and sub-contractors involved in the provision of the Services
 hold and maintain appropriate cover;

The Provider must put in place and/or maintain in force (and/or procure that its sub-contractors must maintain in force) at its own cost appropriate indemnity arrangements in respect of clinical negligence where the provision or non-provision of any part of the Services (or any other services under this Contract) may result in a clinical negligence claim.

3.5 Business Continuity

The Service Provider must ensure that sufficient staffing is available for the effective running of the service, including contingency planning for times of sickness, absences or any other occurrence that may jeopardise the delivery of the service to service users at levels sufficient to meet the performance objectives and service standards of the service as outlined in this agreement.

3.6 Buildings and Accommodation

The service provider will be responsible for sourcing buildings that have the appropriate planning permission for delivering public health services.

The service provider will be responsible for the maintenance costs of any buildings occupied for delivering services, which includes fittings, equipment, repairs and alterations. The provider will be responsible for any costs associated with the replacement of furniture, maintenance and calibration of equipment and the safe disposal of the same, and provide consumables required for the smooth operation of the building.

3.7 Additional Costs

The provider is responsible for all community prescribing costs within the contract value (excluding GP prescribing and dispensing) The provider will be responsible for registering with the NHS Business Services Authority as an Independent Sector Healthcare Provider and informing the NHS Business Services Authority of all their prescribing details for ePact and in order to obtain prescription pads.

The provider will co-operate with the commissioners around access requirements to ePact and prescribing data.

3.8 Communication and Marketing

Providers will have the responsibility for ensuring interpreter services are available when required.

All costs in relation to communication and marketing will be met by the provider.

3.9 Consulting with users

Health & Wellbeing

Foresight (2008). Mental Capital and Wellbeing Project Report.

Government's Foresight project on Mental Capital and Wellbeing, this report recommends five ways to well-being. It presents the evidence and rationale between each of the five ways, drawing on a wealth of psychological literature. In line with similar messages for healthy eating, these are Connect, Be active, Take Notice, Keep Learning and Give.

The service will be highly encouraged to promote wellbeing in the workplace.

4. Referral, Access and Acceptance Criteria

4.1 Geographic coverage/ boundaries

Community Pharmacies in Blackburn with Darwen.

4.2 Location(s) of service delivery

Approved pharmacies in Blackburn with Darwen. The pharmacy must have a consultation area available which is fit for purpose and suitable for confidential discussions. The consultation area as a minimum must meet the requirements set out for advanced services within the NHS community pharmacy contractual framework i.e. be clearly signposted as a private consultation area, be able to seat the pharmacist and the client and allow them to talk in the area at normal speaking volumes without being overheard.

4.3 Days/ hours of operation

The service will operate during pharmacy opening hours.

4.4 Referral criteria and sources

This service is an open referral service and therefore anyone can refer people in, including any healthcare professionals and self-referral.

4.5 Exclusion criteria

There may be some situations where, based on the information obtained, the accredited pharmacist is unable to supply under the terms of the PGD. In these situations, the scheme requires the pharmacist to urgently refer the client to an alternative provider (appendix 1). The client must be made completely aware of the decreasing effectiveness of EHC with time.

4.6 Response time

Clients will be moved to the consultation area as 4.2, to meet with the accredited pharmacist as soon as possible or if an accredited pharmacist is not available, signposted appropriately.

4.7 Applicable service standards – national/local/statutory

All serious and other untoward incidents must be reported to the local authority within 2 working days of the incident as per the Public Health Serious Incidence policy (embedded within the Blackburn with Darwen Public Health Contract). The service must then provide an outlined report of the incident and its outcome within 45 days of notification of the incident.

5. Discharge Criteria and Planning

According to the Public Health Contract

6. Service Improvement Requirements

7. Baseline Performance Targets – Quality, Performance & Productivity

Performance Indicator	Threshold	Method of Measurement	Frequency of Monitoring
Quality - Key Performance Indicators and Outcome Indicators			
Personalised Care Planning All verbal counselling will be supported by written information	100% of all women provided with counselling should have written as well as verbal communication	Audit	Quarterly
Clearly documented complaints procedure in place	100% reporting	Audit	Annually
Patient assessment form completed for every assessment	100% of all consultations must have their assessment recorded on PharmOutcomes	Audit	Quarterly
Appropriate recording of patient safeguarding information and processes completed.	!00% reporting	Audit	Quarterly
Number of clients presenting when accredited pharmacist is not on premises	100% reporting	Number of BwD clients presenting	Quarterly
8. Activity			l
8.1 Activity			

Activity Performance Indicators

Service Area:			
Туре	Threshold	Method of	Frequency of
туре	Theshold	Measurement	Monitoring
		Number of BwD	
Number of clients referred to other services	100% reporting	clients referred	Quarterly

Number of clients classed as unsuitable for the service and reasons why	100% reporting	Number of BwD clients classed as unsuitable for the service	Quarterly
Number of pregnancy tests carried out	100% reporting	Number of pregnancy tests carried out on BwD clients	Quarterly

9. Finance

9.1 Finance

Basis of Contract & Breakdown		
Block		
£15.00 for every completed and documented emergency hormonal contraception consultation with an accredited pharmacist	£15.00	
The list price for Levonelle 1500 stated in the current Drug Tariff) + VAT (Note: NOT Levonelle OTC pack;	List price	
£5 per documented pregnancy test undertaken	£5.00	

Claims are to be submitted via PharmOutcomes by the 5th of each Month, any after this date will not be processed until the following month.

Claims must be submitted not later than 2 months after the month of the claim (for example March claim can be submitted in April or May), therefore they can be submitted quarterly.

However, if they are submitted after the 2 month grace period they may not be approved for payment.

10. Reviews/Monitoring

Monitoring will be via PharmOutcomes in the first instance. Quality review meetings/visits may be instigated at the commissioner's request.

Appendix 1

Blackburn with Darwen Integrated Sexual Health Service

For more information about the sexual health services or help to access support contact: (01254) 268700 or visit: <u>www.brook.org.uk</u>

Chlamydia Screening Service

Brook 54 – 56 Darwen Street Blackburn BB2 2BL Telephone: 01254 268700 Website: www.brook.org.uk

COMMISSIONED SERVICES - PUBLIC HEALTH, BLACKBURN with DARWEN BOROUGH COUNCIL Patient Assessment Form for Emergency Hormonal Contraception (Levonorgestrel 1500 micrograms)

FRASER COMPETENCE AND CONFIDENTIALITY

This section must be completed for all patients less than 16 years of age or where competence is in doubt

Whilst it is permissible to offer young people confidential contraceptive advice they must be made aware that there can be rare occasions when this confidentiality may be broken and other agencies involved. This is usually if the professional suspects that someone is hurting or harming the patient. In some situations, such as where there is a discrepancy in age between a very young patient (under 14) and their partner, concerns may be raised. If you are unsure, discuss the situation with a colleague or contact the designated Child Protection Nurse. It is probably not in the patient's best interests to withhold emergency contraception but record keeping should reflect details of the consultation.

Does the patient understand the advice given, the potential risks and benefits of treatment, and has sufficient maturity to understand what is involved in terms of moral, social and emotional implications?		Yes		No
Has the patient been encouraged to involve her parents or to allow the healthcare				
professional to?		Yes		No
Has the possible effect on the physical or mental health of the patient, it treatment were				
withheld, been considered?		Yes		No
Is providing contraceptive advice and treatment in the best interest of the patient?				
		Yes		No
All the above areas must be fully discussed during the consultation which should be do	ocument	ed and	include	and

All the above areas must be fully discussed during the consultation which should be documented and include and assessment of the patient's maturity. If any question is answered 'No', the patient must be referred.

PATIENT HISTORY			
Date of Consultation:			
ID Number/ Name (initials)			
Age of Patient:		Age of Partner:	
Patient's usual General Practitioner (GP)		First Four Digits of Patient's Postcode:	
Date of, or time since, start of Last (LMP):	Menstrual Period		
Details of when UPSI occurred:		Day of Cycle: Time:	
		Hours elapsed since:	
How many days is each normal cyc		and is regular / irregular * (* d	elete as applicable)
Reason for seeking Emergency	Contraception:	1. No contraceptive used	
(*ring applicable nu	mber)	2. Failed barrier method of contracept	
		 Missed or incorrectly used combin contraceptive pill 	ned or progestogen only
		 Contraceptive pill vomited or af medicines 	fected by diarrhoea or
		5. Late depot injection	
		6. Removal or loss of implant / intraute	erine device/system
		 Missed, incorrectly used, affected a contraceptive patch/vaginal ring 	by medicines or removed
		8. Vomited supplied course of EC	
		9. Loss of protection following change	in contraceptive method
		10. Other appropriate reason (state):	·

A: Has the patient had unprotected sexual intercourse (UPSI) in this menstrual cycle? Yes No B: Did this episode of UPSI occur within the last 72 hours, (120 hours if the patient takes or has Yes No B: Did this episode of UPSI occur within the last 72 hours, (120 hours if thipristal Acetate is contraindicated)? No No C: All emergency contraceptive options (including mode of action and failure rates) discussed Yes No To be eligible for supply, the patient should be referred? Po OD Contraceptive Service. EXCLUSION CRITERIA D. Has the patient ever had an allergic reaction/ severe adverse effect to Levonelle or any Yes No F. Was the last menstrual period (LMP) more than four weeks ago? Yes No G. was the LMP abnormal in any way (e.g. different length or flow), or any unexplained or unsubla vaginal bleeding in the current cycle? Yes No H. Has the patient used ulpristal acetate (EliaOne) in the previous 5 days? Yes No No J. Does the patient suffer with lactose intolerance? Yes No No K. Is the patient currently or has taken in the last 28 days liver enzyme inducers (give double dose) including Carbamazepine, Ciclosporin, Grisofuluin, nevirapine, oxcarbazine, phenytoin, primidone or other barbiturates, rifabultin, rifampicin, ritonavir, modafinil, SI Johr's Wort or torear wy other ediciotan that may interact with EC?			
recently taken liver enzyme inducing drugs; or between 72 and 120 hours if Ulipristal Acetate is or a contraindicated)? C: All emergency contraceptive options (including mode of action and failure rates) discussed Yes No To be eligible for supply of the vonelle-1500 under this service specification, the answers to A, B AND C must be YES. If any of these do not apply, the patient should be referred to a GP or Doctor Led Contraceptive Service. EXCLUSION CONTERIA D. Has the patient ever had an allergic reaction/ severe adverse effect to Levonelle or any Yes No E. Have there been any other episodes of UPSI in the last three weeks for which the patient has Yes No G. was the LMP abnormal in any way (e.g. different length or flow), or any unexplained or Yes No G. was the LMP abnormal in any way (e.g. different length or flow), or any unexplained or Yes No G. was the LMP abnormal in any way (e.g. different length or flow), or any unexplained or Yes No G. Was the patient used ulpristal acetate (EllaOne) in the previous 5 days? H. Has the patient used ulpristal acetate (EllaOne) in the previous 5 days? H. Has the patient current cycle? No L. Are there any child protection issues or serious concerns? No K. Is the patient currently or has taken in the last 28 days liver enzyme inducers (glve double dose) including Carbamazepine, Ciclosporin, Griseofulwin, mexirapine, oxcarbazine, phenytoin, Yes No K. Is the patient current by or has taken in the last 28 days liver enzyme inducers (glve double dose) including Carbamazepine, Ciclosporin, Griseofulwin, mexirapine, oxcarbazine, phenytoin, Yes No K. Is the patient to ror G is Yes', acclude pregnancy before proceeding. If pregnant, refer to GP or Specialist Sexual Health Service. If the answer to I is Yes', advise that the efficacy of ulpristal acetate may be reduced. Proceed if it is in the patient's best interests. Whether proceeding or not, refer as appropriate and involve child protection team. If the answer to I is Yes' and UD is declined, issue double dose of levonorgestr	A: Has the patient had unprotected sexual intercourse (UPSI) in this menstrual cycle?	Yes	No
with the patient and hormonal method preferred? No To be eligible for supply of Levonelle-1500 under this service specification, the answers to A, B AND C mus be YES. If any of these do not apply, the patient should be referred to a GP or Doctor Led Contraceptive Service. EXCLUSION CRITERIA	recently taken liver enzyme inducing drugs; or between 72 and 120 hours if Ulipristal Acetate is	Yes	□ No
To be eligible for supply of Levonelle-1500 under this service specification, the answers to A, B AND C must be YES. If any of these do not apply, the patient should be referred to a GP or Doctor Led Contraceptive Service. EXCLUSION CRITERIA D. Has the patient ever had an allergic reaction/ severe adverse effect to Levonelle or any contraception? Ves E. Have there been any other episodes of UPSI in the last three weeks for which the patient has voor contraception? Ves No E. Have there been any other episodes of UPSI in the last three weeks for which the patient has voor contraception? No No E. Was the last menstrual period (LMP) more than four weeks ago? Ves No G. was the LMP abnormal in any way (e.g. different length or flow), or any unexplained or unusual vaginal bleeding in the current cycle? No H. Has the patient used ulipristal acetate (EllaOne) in the previous 5 days? Yes No I. Are there any child protection issues or serious concerns? Yes No J. Does the patient suffer with lactose intolerance? Yes No K. Is the patient currently or has taken in the last 28 days liver enzyme inducers (give double dose) including Carbamazepine, Ciclosporin, Griseofulvin, nevirapine, oxcarbazine, phenytoin, primidone or other barbiturates, rifabutin, rifampicin, ritonavir, modafinil, St John's Wort or topiramate or any other medication that may interact with EC? No If the answer to H is Yes', acklude pregnancy before proceedi		Yes	No
EXCLUSION CRITERIA D. Has the patient ever had an allergic reaction/ severe adverse effect to Levonelle or any Yes			st be YES. If
D. Has the patient ever had an allergic reaction/ severe adverse effect to Levonelle or any location ingredient? No E. Have there been any other episodes of UPSI in the last three weeks for which the patient has No Yes No F. Was the last menstrual period (LMP) more than four weeks ago? Yes No G. was the LMP abnormal in any way (e.g. different length or flow), or any unexplained or yes Yes No H. Has the patient used ulipristal acetate (EllaOne) in the previous 5 days? Yes No I. Are there any child protection issues or serious concerns? Yes No J. Does the patient suffer with lactose intolerance? No No J. Does the patient currently or has taken in the last 28 days liver enzyme inducers (give double dose) including Carbamazepine, Cicosporti, Grisofulvin, nevirapine, occarbazine, phenytoin, Yes No Modeling Carbamazepine, Cicosporti, Grisofulvin, nevirapine, occarbazine, phenytoin, Yes No No If the answer to F or G is 'Yes', advise that the efficacy of ulipristal acetate may be reduced. Proceed if it is in the patient's best interests and strongly recommend IUD. If the answer to K is 'Yes' and IUD is declined, issue double dose of levonorgestrel 1500 microgram. If the answer to K is 'Yes' and IUD is declined, issue double dose of levonorgestrel 1500 microgram. No If the answer to K is 'Yes' and IUD is declined, issue double dose of levonorgestrel 1500 mic		Seivice.	
E. Have there been any other episodes of UPSI in the last three weeks for which the patient has Yes NOT had emergency contraception? No F. Was the last menstrual period (LMP) more than four weeks ago? Yes G. was the LMP abnormal in any way (e.g. different length or flow), or any unexplained or No I. Mas the patient used ulipristal acetate (EllaOne) in the previous 5 days? Yes H. Has the patient used ulipristal acetate (EllaOne) in the previous 5 days? Yes I. Are there any child protection issues or serious concerns? Yes J. Does the patient suffer with lactose intolerance? No K. Is the patient currently or has taken in the last 28 days liver enzyme inducers (give double does) including Carbamazepine, Ciclosporin, Griseofulvin, nevirapine, oxcarbazine, phenytoin, primidone or other barbiturates, rifabutin, rifampicin, ritonavir, modafinil, St John's Wort or topiramate or any other medication that may interact with EC? (Remember to cross check brand names) If the answer to F or G is 'Yes', exclude pregnancy before proceeding. If pregnant, refer to GP or Specialist Sexual Health Service. If the answer to I is 'Yes', nocced if it is in the patient's best interests. Whether proceeding or not, refer as appropriate and involve child protection team. If the answer is Yes' to ANY other question, the patient's best interests. Whether proceeding or not, refer as appropriate and involve child protection team. If the answer is Yes' to ANY other question, the patient should be referred to a GP or Doctor Led Contraceptive Session PATIENT COUNSELLING All the following subjects must be raised / discussed with the patient before supply Possible adverse e	D. Has the patient ever had an allergic reaction/ severe adverse effect to Levonelle or any	Yes	
F. Was the last menstrual period (LMP) more than four weeks ago? Yes No G. was the LMP abnormal in any way (e.g. different length or flow), or any unexplained or unusual vaginal bleeding in the current cycle? No H. Has the patient used ulipristal acetate (EllaOne) in the previous 5 days? Yes No I. Are there any child protection issues or serious concerns? Yes No J. Does the patient suffer with lactose intolerance? Yes No K. Is the patient currently or has taken in the last 28 days liver enzyme inducers (give double dose) including Carbamazepine, Ciclosporin, Griseofulvin, nevirapine, oxcarbazine, phenytoin, primidone or other barbiturates, infabutin, rifampicin, ritonavir, modafinil, St John's Wort or topiramate or any other medication that may interact with EC? No If the answer to F or G is Yes', advise that the efficacy of ulipristal acetate may be reduced. Proceed if it is in the patient's best interests and strongly recommend IUD. If the answer to K is Yes', ad UID is declined, issue double dose of levonorgestrel 1500 microgram. If the answer to K is Yes' and IUD is declined, issue double dose of levonorgestrel 1500 microgram. No Patient Coursective No Advise that levonorgestrel 1500 microgram is not 100% effective and that pregnancy can still Yes If the answer to K is Yes' and IUD is declined, issue double dose of levonorgestrel 1500 microgram. No PATIENT COUNSELLING No <td>E. Have there been any other episodes of UPSI in the last three weeks for which the patient has</td> <td>Yes</td> <td></td>	E. Have there been any other episodes of UPSI in the last three weeks for which the patient has	Yes	
G. was the LMP abnormal in any way (e.g. different length or flow), or any unexplained or unusual vaginal bleeding in the current cycle? No H. Has the patient used ulipristal acetate (EllaOne) in the previous 5 days? Yes No I. Are there any child protection issues or serious concerns? Yes No J. Does the patient suffer with lactose intolerance? Yes No K. Is the patient currently or has taken in the last 28 days liver enzyme inducers (give double dose) including Carbamazepine, Ciclosporin, Griseofulvin, nevirapine, oxcarbazine, phenytoin, primidone or other barbiturates, rifabutin, rifampicin, ritonavir, modafinil, St John's Wort or topiramate or any other medication that may interact with EC? No If the answer to F or G is 'Yes', exclude pregnancy before proceeding. If pregnant, refer to GP or Specialist Sexual Health Service. If the answer to K is 'Yes' and UD is declined, issue double dose of levonorgestrel 1500 microgram. If the answer to K is 'Yes' and UD is declined, issue double dose of levonorgestrel 1500 microgram. If the following subjects must be raised / discussed with the patient before supply No Possible adverse effects, including possible ectopic pregnancy, and action to take if they occur Yes No No Mother to take levonorgestrel 1500 microgram is on 100% effective and that pregnancy can still Yes No No Advise that levonorgestrel 1500 microgram and action to take if vomiting occurs<		Yes	
H. Has the patient used ulipristal acetate (EllaOne) in the previous 5 days? Yes No I. Are there any child protection issues or serious concerns? Yes No J. Does the patient suffer with lactose intolerance? Yes No K. Is the patient currently or has taken in the last 28 days liver enzyme inducers (give double dose) including Carbamazepine, Ciclosporin, Griseofulvin, nevirapine, oxcarbazine, phenytoin, primidone or other barbiturates, rifabutin, rifampicin, ritonavir, modafinil, St John's Wort or topiramate or any other medication that may interact with EC? No If the answer to F or G is Yes', exclude pregnancy before proceeding. If pregnant, refer to GP or Specialist Sexual Health Service. If the answer to T is Yes', proceed if it is in the patient's best interests. Whether proceeding or not, refer as appropriate and involve child protection team. If the answer to K is 'Yes' and IUD is declined, issue double dose of levonorgestrel 1500 microgram. If the following subjects must be raised / discussed with the patient before supply Possible adverse effects, including possible ectopic pregnancy, and action to take if they occur Yes No Advise that levonorgestrel 1500 microgram is not 100% effective and that pregnancy can still Yes No Possible adverse effects on the foetus if pregnancy occurred- no evidence of adverse effect but No No Possible effects on the foetus if pregnancy cannot be guaranteed. No No		Yes	
1. Are there any child protection issues or serious concerns? Yes No 1. Does the patient suffer with lactose intolerance? Yes No K. Is the patient currently or has taken in the last 28 days liver enzyme inducers (give double dose) including Carbamazepine, Ciclosporin, Griseofulvin, nevirapine, oxcarbazine, phenytoin, primidone or other barbiturates, rifabutin, rifampicin, ritonavir, modafinil, St John's Wort or topiramate or any other medication that may interact with EC? (<i>Remember to cross check brand names</i>) No If the answer to F or G is 'Yes', acdude pregnancy before proceeding. If pregnant, refer to GP or Specialist Sexual Health Service. If the answer to F or G is 'Yes', advise that the efficacy of ulipristal acetate may be reduced. Proceed if it is in the patient's best interests and strongly recommend IUD. If the answer to I is 'Yes', advise that the efficacy of ulipristal acetate may be reduced. Proceed if it is in the patient's best interests. Whether proceeding or not, refer as appropriate and involve child protection team. If the answer to I is 'Yes' and IUD is declined, issue double dose of levonorgestrel 1500 microgram. If the answer to K is 'Yes' and IUD is declined, issue double dose of levonorgestrel 1500 microgram. If the answer to K is 'Yes' and UD is declined, issue double dose of levonorgestrel 1500 microgram. No Advise that levonorgestrel 1500 microgram is not 100% effective and that pregnancy can still No Advise that levonorgestrel 1500 microgram and action to take if they occur No No No		Yes	
J. Does the patient suffer with lactose intolerance? Image: the suffer with lactose intolerance? No K. Is the patient currently or has taken in the last 28 days liver enzyme inducers (give double dose) including Carbamazepine, Ciclosporin, Griseofulvin, nevirapine, oxcarbazine, phenytoin, Image: the suffer with lactose intolerance, into any other medication that may interact with EC? No <i>primidone or other barbiturates, rifabutin, rifampicin, ritonavir, modafinil, St John's Wort or topiramate or any other medication that may interact with EC? (Remember to cross check brand names)</i> If the answer to F or G is 'Yes', advise that the efficacy of ulipristal acetate may be reduced. Proceed if it is in the patient's best interests and strongly recommend IUD. If the answer to I is 'Yes', proceed if it is in the patient's best interests. Whether proceeding or not, refer as appropriate and involve child protection team. If the answer to K is 'Yes' and IUD is declined, issue double dose of levonorgestrel 1500 microgram. If the answer is 'Yes' to ANY other question, the patient should be referred to a GP or Doctor Led Contraceptive Session PATIENT COUNSELLING Advise that levonorgestrel 1500 microgram is not 100% effective and that pregnancy can still Yes No No Advise that levonorgestrel 1500 microgram and action to take if vomiting occurs No	I. Are there any child protection issues or serious concerns?	Yes	No
K. Is the patient currently or has taken in the last 28 days liver enzyme inducers (give double dose) including Carbamazepine, Ciclosporin, Griseofulvin, nevirapine, oxcarbazine, phenytoin, primidone or other barbiturates, rifabutin, rifampicin, ritonavir, modafinil, St John's Wort or topiramate or any other medication that may interact with EC? (Remember to cross check brand names) Yes No If the answer to F or G is 'Yes', exclude pregnancy before proceeding. If pregnant, refer to GP or Specialist Sexual Health Service. If the answer to H is 'Yes', advise that the efficacy of ulipristal acetate may be reduced. Proceed if it is in the patient's best interests and strongly recommend IUD. If the answer to I is 'Yes', advise that the efficacy of ulipristal acetate may be reduced. Proceed if it is in the patient's best interests and strongly recommend IUD. If the answer to I is 'Yes', advise that the efficacy of ulipristal acetate may be reduced. Proceed if it is in the patient's best interests. Whether proceeding or not, refer as appropriate and involve child protection team. If the answer to I is 'Yes' and IUD is declined, issue double dose of levonorgestrel 1500 microgram. If the following subjects must be raised / discussed with the patient before supply Possible adverse effects, including possible ectopic pregnancy, and action to take if they occur Yes No Advise that levonorgestrel 1500 microgram is not 100% effective and that pregnancy can still Yes No Possible affects on the foetus if pregnancy occurred- no evidence of adverse effect but No N	J. Does the patient suffer with lactose intolerance?	Yes	No
dose) including Carbamazepine, Ciclosporin, Griseofulvin, nevirapine, oxcarbazine, phenytoin, primidone or other barbiturates, rifabutin, rifampicin, ritonavir, modafinil, St John's Wort or topiramate or any other medication that may interact with EC? Yes No Remember to cross check brand names) If the answer to F or G is 'Yes', exclude pregnancy before proceeding. If pregnant, refer to GP or Specialist Sexual Health Service. If the answer to H is 'Yes', advise that the efficacy of ulipristal acetate may be reduced. Proceed if it is in the patient's best interests and strongly recommend IUD. If the answer to I is 'Yes', proceed if it is in the patient's best interests. Whether proceeding or not, refer as appropriate and involve child protection team. If the answer to K is 'Yes' and IUD is declined, issue double dose of levonorgestrel 1500 microgram. If the answer is 'Yes' to ANY other question, the patient should be referred to a GP or Doctor Led Contraceptive Session PATIENT COUNSELLING	K. Is the patient currently or has taken in the last 28 days liver enzyme inducers (<i>give double</i>		No
topiramate or any other medication that may interact with EC? (Remember to cross check brand names) If If the answer to F or G is 'Yes', exclude pregnancy before proceeding. If pregnant, refer to GP or Specialist Sexual Health Service. If the answer to H is 'Yes', advise that the efficacy of ulipristal acetate may be reduced. Proceed if it is in the patient's best interests and strongly recommend IUD. If the answer to I is 'Yes', proceed if it is in the patient's best interests. Whether proceeding or not, refer as appropriate and involve child protection team. If the answer to K is 'Yes' and IUD is declined, issue double dose of levonorgestrel 1500 microgram. If the answer is 'Yes' to ANY other question, the patient should be referred to a GP or Doctor Led Contraceptive Session PATIENT COUNSELLING All the following subjects must be raised / discussed with the patient before supply Possible adverse effects, including possible ectopic pregnancy, and action to take if they occur Yes No Advise that levonorgestrel 1500 microgram is not 100% effective and that pregnancy can still Yes occur No Possible effects on the foetus if pregnancy occurred- no evidence of adverse effect but Yes No No The need to abstain from intercourse or to consistently and correctly use a reliable barrier method of contraception for at least until the next menstrual period. Other hormonal contraception may be continued No Futur	dose) including Carbamazepine, Ciclosporin, Griseofulvin, nevirapine, oxcarbazine, phenytoin,	Yes	🗆 No
If the answer to F or G is 'Yes', exclude pregnancy before proceeding. If pregnant, refer to GP or Specialist Sexual Health Service. If the answer to H is 'Yes', advise that the efficacy of ulipristal acetate may be reduced. Proceed if it is in the patient's best interests and strongly recommend IUD. If the answer to I is 'Yes', proceed if it is in the patient's best interests. Whether proceeding or not, refer as appropriate and involve child protection team. If the answer to K is 'Yes' and IUD is declined, issue double dose of levonorgestrel 1500 microgram. If the answer is 'Yes' to ANY other question, the patient should be referred to a GP or Doctor Led Contraceptive Session PATIENT COUNSELLING All the following subjects must be raised / discussed with the patient before supply Possible adverse effects, including possible ectopic pregnancy, and action to take if they occur Yes No Advise that levonorgestrel 1500 microgram is not 100% effective and that pregnancy can still Yes occur No Possible effects on the foetus if pregnancy occurred- no evidence of adverse effect but Yes No No How to take levonorgestrel 1500 microgram and action to take if vomiting occurs Yes No No The need to abstain from intercourse or to consistently and correctly use a reliable barrier method of contraception for at least until the next menstrual period. Other hormonal contraception may be continued <td>topiramate or any other medication that may interact with EC?</td> <td></td> <td></td>	topiramate or any other medication that may interact with EC?		
Service. If the answer to H is 'Yes', advise that the efficacy of ulipristal acetate may be reduced. Proceed if it is in the patient's best interests and strongly recommend IUD. If the answer to I is 'Yes', proceed if it is in the patient's best interests. Whether proceeding or not, refer as appropriate and involve child protection team. If the answer to K is 'Yes' and IUD is declined, issue double dose of levonorgestrel 1500 microgram. If the answer to K is 'Yes' to ANY other question, the patient should be referred to a GP or Doctor Led Contraceptive Session PATIENT COUNSELLING All the following subjects must be raised / discussed with the patient before supply Possible adverse effects, including possible ectopic pregnancy, and action to take if they occur Yes No Advise that levonorgestrel 1500 microgram is not 100% effective and that pregnancy can still Yes occur No Possible effects on the foetus if pregnancy occurred- no evidence of adverse effect but Yes No No How to take levonorgestrel 1500 microgram and action to take if vomiting occurs Yes No No The need to abstain from intercourse or to consistently and correctly use a reliable barrier method of contraception for at least until the next menstrual period. Other hormonal contraceptive needs No Future contraceptive needs Yes No N		Consistint Co	
best interests and strongly recommend IUD. If the answer to I is 'Yes', proceed if it is in the patient's best interests. Whether proceeding or not, refer as appropriate and involve child protection team. If the answer to K is 'Yes' and IUD is declined, issue double dose of levonorgestrel 1500 microgram. If the answer to K is 'Yes' and IUD is declined, issue double dose of levonorgestrel 1500 microgram. If the answer to K is 'Yes' and IUD is declined, issue double dose of levonorgestrel 1500 microgram. If the answer is 'Yes' to ANY other question, the patient should be referred to a GP or Doctor Led Contraceptive Session PATIENT COUNSELLING All the following subjects must be raised / discussed with the patient before supply Possible adverse effects, including possible ectopic pregnancy, and action to take if they occur Yes No Advise that levonorgestrel 1500 microgram is not 100% effective and that pregnancy can still Yes occur No Possible effects on the foetus if pregnancy occurred- no evidence of adverse effect but Yes successful outcome of any pregnancy cannot be guaranteed. No How to take levonorgestrel 1500 microgram and action to take if vomiting occurs Yes No No The need to abstain from intercourse or to consistently and correctly use a reliable barrier No No No <td></td> <td>Specialist Se</td> <td>xual Health</td>		Specialist Se	xual Health
If the answer to I is 'Yes', proceed if it is in the patient's best interests. Whether proceeding or not, refer as appropriate and involve child protection team. If the answer to K is 'Yes' and IUD is declined, issue double dose of levonorgestrel 1500 microgram. If the answer to K is 'Yes' and IUD is declined, issue double dose of levonorgestrel 1500 microgram. If the answer to K is 'Yes' and IUD is declined, issue double dose of levonorgestrel 1500 microgram. If the answer to K is 'Yes' and IUD is declined, issue double dose of levonorgestrel 1500 microgram. PATIENT COUNSELLING All the following subjects must be raised / discussed with the patient before supply Possible adverse effects, including possible ectopic pregnancy, and action to take if they occur Yes Advise that levonorgestrel 1500 microgram is not 100% effective and that pregnancy can still Yes occur No Possible effects on the foetus if pregnancy occurred- no evidence of adverse effect but Yes successful outcome of any pregnancy cannot be guaranteed. No How to take levonorgestrel 1500 microgram and action to take if vomiting occurs Yes no No The need to abstain from intercourse or to consistently and correctly use a reliable barrier No rethod of contraception for at least until the next menstrual period. Other hormonal		ed if it is in tl	ne patient's
and involve child protection team. If the answer to K is 'Yes' and IUD is declined, issue double dose of levonorgestrel 1500 microgram. If the answer is 'Yes' to ANY other question, the patient should be referred to a GP or Doctor Led Contraceptive Session PATIENT COUNSELLING All the following subjects must be raised / discussed with the patient before supply Possible adverse effects, including possible ectopic pregnancy, and action to take if they occur Yes Advise that levonorgestrel 1500 microgram is not 100% effective and that pregnancy can still Yes occur No Possible effects on the foetus if pregnancy occurred- no evidence of adverse effect but Yes If he need to abstain from intercourse or to consistently and correctly use a reliable barrier Yes method of contraception for at least until the next menstrual period. Other hormonal contraceptive needs No Future contraceptive needs Yes No			
If the answer to K is 'Yes' and IUD is declined, issue double dose of levonorgestrel 1500 microgram. If the answer is 'Yes' to ANY other question, the patient should be referred to a GP or Doctor Led Contraceptive Session PATIENT COUNSELLING All the following subjects must be raised / discussed with the patient before supply Possible adverse effects, including possible ectopic pregnancy, and action to take if they occur Yes Advise that levonorgestrel 1500 microgram is not 100% effective and that pregnancy can still Yes occur No Possible effects on the foetus if pregnancy occurred- no evidence of adverse effect but Yes successful outcome of any pregnancy cannot be guaranteed. No How to take levonorgestrel 1500 microgram and action to take if vomiting occurs Yes The need to abstain from intercourse or to consistently and correctly use a reliable barrier No Rethod of contraception for at least until the next menstrual period. Other hormonal contraception may be continued Yes Future contraceptive needs Yes No That Levonelle-1500 does not protect against sexually transmitted diseases and the actions to Yes		not, refer as a	appropriate
If the answer is 'Yes' to ANY other question, the patient should be referred to a GP or Doctor Led Contraceptive Session PATIENT COUNSELLING All the following subjects must be raised / discussed with the patient before supply Possible adverse effects, including possible ectopic pregnancy, and action to take if they occur Yes Advise that levonorgestrel 1500 microgram is not 100% effective and that pregnancy can still Yes occur No Possible effects on the foetus if pregnancy occurred- no evidence of adverse effect but Yes successful outcome of any pregnancy cannot be guaranteed. No How to take levonorgestrel 1500 microgram and action to take if vomiting occurs Yes no No The need to abstain from intercourse or to consistently and correctly use a reliable barrier Yes method of contraception for at least until the next menstrual period. Other hormonal contraception may be continued Yes Future contraceptive needs Yes No That Levonelle-1500 does not protect against sexually transmitted diseases and the actions to Yes Image: No		ram.	
All the following subjects must be raised / discussed with the patient before supply Possible adverse effects, including possible ectopic pregnancy, and action to take if they occur Yes Advise that levonorgestrel 1500 microgram is not 100% effective and that pregnancy can still Yes Occur No Possible effects on the foetus if pregnancy occurred- no evidence of adverse effect but Yes Successful outcome of any pregnancy cannot be guaranteed. No How to take levonorgestrel 1500 microgram and action to take if vomiting occurs Yes The need to abstain from intercourse or to consistently and correctly use a reliable barrier Yes method of contraception for at least until the next menstrual period. Other hormonal contraceptive needs Yes Future contraceptive needs Yes No	If the answer is 'Yes' to ANY other question, the patient should be referred to a GP or Doctor Le	d Contracept	tive Session
All the following subjects must be raised / discussed with the patient before supply Possible adverse effects, including possible ectopic pregnancy, and action to take if they occur Yes Advise that levonorgestrel 1500 microgram is not 100% effective and that pregnancy can still Yes Occur No Possible effects on the foetus if pregnancy occurred- no evidence of adverse effect but Yes Successful outcome of any pregnancy cannot be guaranteed. No How to take levonorgestrel 1500 microgram and action to take if vomiting occurs Yes The need to abstain from intercourse or to consistently and correctly use a reliable barrier Yes method of contraception for at least until the next menstrual period. Other hormonal contraceptive needs Yes Future contraceptive needs Yes No			
Possible adverse effects, including possible ectopic pregnancy, and action to take if they occur Yes No Advise that levonorgestrel 1500 microgram is not 100% effective and that pregnancy can still Yes No Occur No No Possible effects on the foetus if pregnancy occurred- no evidence of adverse effect but Yes No Possible effects on the foetus if pregnancy cannot be guaranteed. No No How to take levonorgestrel 1500 microgram and action to take if vomiting occurs Yes No The need to abstain from intercourse or to consistently and correctly use a reliable barrier method of contraception for at least until the next menstrual period. Other hormonal contraceptive needs Yes No Future contraceptive needs Yes No No That Levonelle-1500 does not protect against sexually transmitted diseases and the actions to Yes I			
Advise that levonorgestrel 1500 microgram is not 100% effective and that pregnancy can still Yes Advise that levonorgestrel 1500 microgram is not 100% effective and that pregnancy can still Yes Occur No Possible effects on the foetus if pregnancy occurred- no evidence of adverse effect but Yes successful outcome of any pregnancy cannot be guaranteed. No How to take levonorgestrel 1500 microgram and action to take if vomiting occurs Yes The need to abstain from intercourse or to consistently and correctly use a reliable barrier Yes method of contraception for at least until the next menstrual period. Other hormonal contraception may be continued Yes Future contraceptive needs Yes No That Levonelle-1500 does not protect against sexually transmitted diseases and the actions to Yes I			
occur No Possible effects on the foetus if pregnancy occurred- no evidence of adverse effect but successful outcome of any pregnancy cannot be guaranteed. Yes How to take levonorgestrel 1500 microgram and action to take if vomiting occurs Yes The need to abstain from intercourse or to consistently and correctly use a reliable barrier method of contraception for at least until the next menstrual period. Other hormonal contraception may be continued Yes Future contraceptive needs Yes No That Levonelle-1500 does not protect against sexually transmitted diseases and the actions to Yes	Possible adverse effects, including possible ectopic pregnancy, and action to take if they occur	Yes	No
successful outcome of any pregnancy cannot be guaranteed. No How to take levonorgestrel 1500 microgram and action to take if vomiting occurs Yes The need to abstain from intercourse or to consistently and correctly use a reliable barrier method of contraception for at least until the next menstrual period. Other hormonal contraception may be continued Yes Future contraceptive needs Yes No That Levonelle-1500 does not protect against sexually transmitted diseases and the actions to Yes Yes		Yes	No
How to take levonorgestrel 1500 microgram and action to take if vomiting occurs Yes No The need to abstain from intercourse or to consistently and correctly use a reliable barrier Yes method of contraception for at least until the next menstrual period. Other hormonal No contraception may be continued Yes Future contraceptive needs Yes That Levonelle-1500 does not protect against sexually transmitted diseases and the actions to Yes		Yes	No
The need to abstain from intercourse or to consistently and correctly use a reliable barrier method of contraception for at least until the next menstrual period. Other hormonal contraception may be continued Yes No Future contraceptive needs Yes No That Levonelle-1500 does not protect against sexually transmitted diseases and the actions to Yes Yes		Yes	
Future contraceptive needs Yes Image: That Levonelle-1500 does not protect against sexually transmitted diseases and the actions to Yes	method of contraception for at least until the next menstrual period. Other hormonal	Yes	
That Levonelle-1500 does not protect against sexually transmitted diseases and the actions to Yes		Yes	
take if the patient is concerned about these No		Yes	

Recommend pregnancy test after four weeks or if next period is late or abnormal in any	way
----------------------------------------------------------------------------------------	-----

Yes No

	ACTION TAKEN			
	Was the patient supplied levonorgestrel 1500 microgram?		Yes	
				No
	Confirm that the dose was taken, supervised at the consultation	1?	Yes	
				No
	Batch Number of Issued Packet:	Expiry Date of Issued Packet:		
	Was the patient referred to another agency? (if 'Yes', state which	ch agency below)	Yes	
				No
	Any further notes:			
CONF	FIRMATION AND CONSENT			
It is re	commended that the patient should sign below to indicate writte	n consent, especially if the consult	tation was d	ifficult.
I confi	irm that the information detailed above has been discussed and	I that I / they understand it.		
This s	upply is for a free of charge contraceptive and no prescription c	harges are due		
Name	of Professional making supply:	Signature:		
		-		
Signat	ure of Patient:			
2				

Appendix 3

MAKING A SECTION 47 REFERRAL

For children residing within Lancashire boundaries including Blackburn with Darwen

The Service Provider shall devise, implement and maintain a procedure for its staff which ensures compliance with pan-Lancashire procedures for Safeguarding Children and Safeguarding Vulnerable Adults, and shall supply a copy of its procedure to the Commissioner before commencement of the service.

Pan Lancashire safeguarding children policies and procedures can be accessed at:

http://panlancashirescb.proceduresonline.com/index.htm


Blackburn with Darwen Safeguarding adult policies and procedures can be accessed at:

Blackburn with Darwen Council Local Safeguarding Adults Board (Isab.org.uk)

The service provider will comply with the lead commissioner's standards for safeguarding as detailed in the CCGs safeguarding policy and will provide evidence of their safeguarding arrangements on request, at a minimum this will be annually.

Possible signs and indicators of child abuse and neglect

Append	ix 4 Physical A	buse		Emotional A	buse
Actions and behaviour of adult/ carer	 Minor injuries Serious head injuries eg. Those resulting in fractures or head injuries Premeditated sadistic injuries Burns and scalds Bites Repeated abuse resulting from lack of control Injury resulting from physical chastisement 	 Shaking Poisoning Physical assaults regarded as bullying Suffocating Fabricated or induced illness Female circumcision Death/murder 	Actions and behaviour of adult/ carer	 Rejection Lack of praise and encouragement Lack of comfort and love Lack of secure attachment Lack of continuity of care eg. frequent moves Serious over protectiveness Inappropriate non-physical punishment eg. locking in bedroom, cold water in bath, frequent shouting at a child 	 Exposure to repeated incidents of domestic abuse Age or developmentally inappropriate expectations being imposed on the child Making the children feel frightened or in danger
Physical signs on child/ young person	 Unconscious Unexplained bruising/marks or injuries Injuries of different ages Adult bite marks 	 Difficulty in moving limbs Blood in white of eyes, small bruises on head, bruises on rib cage—may be associated with shaking injuries 		 Humiliating and degrading behaviour, including bullying and racial abuse 	
	 Adult bite marks Outline bruising eg. belt, hand print Bruises to eyes, ears, finger tips Burns and scalds on hands, feet, buttock, groin, dgarette burns 	 Injuries and/or fractures in babies and children who are not mobile Drowsiness eg. from head injury or poisoning Female genital mutilation Genital/anal area injuries 	Physical signs on child/ young person	 Self harm behaviour, eg. mutilation, substance misuse, suicide attempts Developmental delay Eating disorders 	
Behaviour and emotional state of child/ young person	 Aggressive Withdrawn or watchful behaviour Low self-esteem Poor concentration Poor self image 	 Flinching when approached or touched 	Behaviour and emotional state of child/ young person	 Aggressive Withdrawn Low self-esteem and self worth Repetitive comfort behaviour eg. rocking or hair twisting Sudden speech disorders 	 No sense of achievement Lack of confidence, lack of positive identity Inability to play Failure to thrive Severe behaviour problems
	Sexual Al	ouse		Neglect	t
Actions and behaviour of adult/ carer	Sexual Al • Inappropriate fondling • Mutual masturbation • Digital penetration • Oral/genital contact • Anal or vaginal intercourse • Sexual exploitation • Exposure to pomography	 Encouraging children/young people to become prostitutes Encouraging children to witness intercourse or pornographic acts Leaving a child in the care of a known sex offender Internet child pornography 	Actions and behaviour of adult/ carer	 Abandonment or desertion Leaving alone Malnourishment, lack of food, inappropriate food or erratic feeding Lack of warmth Lack of protection or lack of 	 Leaving child alone to care for younger siblings Lack of appropriate stimulation Lack of protection from dangerous substances eg. fire, drugs, chemicals Lack of appropriate medical care Lack of secure attachment
behaviour of adult/ carer Physical	 Inappropriate fondling Mutual masturbation Digital penetration Oral/genital contact Anal or vaginal intercourse Sexual exploitation Exposure to pornography Injuries to the genital/anal area 	 Encouraging children/young people to become prostitutes Encouraging children to witness intercourse or pornographic acts Leaving a child in the care of a known sex offender Internet child pornography Self harm eg. suicide, self 	behaviour of	 Abandonment or desertion Leaving alone Malnourishment, lack of food, inappropriate food or erratic feeding Lack of warmth Lack of adequate clothing 	 Leaving child alone to care for younger siblings Lack of appropriate stimulation Lack of protection from dangerous substances eg. fire, drugs, chemicals Lack of appropriate medical care
behaviour of adult/ carer	 Inappropriate fondling Mutual masturbation Digital penetration Oral/genital contact Anal or vaginal intercourse Sexual exploitation Exposure to pornography 	 Encouraging children/young people to become prostitutes Encouraging children to witness intercourse or pornographic acts Leaving a child in the care of a known sex offender Internet child pornography 	behaviour of	 Abandonment or desertion Leaving alone Malnourishment, lack of food, inappropriate food or erratic feeding Lack of warmth Lack of adequate clothing Lack of protection or lack of supervision appropriate to child's age and developmental stage Persistent failure to attend school Delayed physical development: underweight and small of stature Hands and feet which are cold and puffy Chronic nappy rash 	 Leaving child alone to care for younger siblings Lack of appropriate stimulation Lack of protection from dangerous substances eg. fire, drugs, chemicals Lack of appropriate medical care Lack of secure attachment
behaviour of adult/ carer Physical signs on child/ young	 Inappropriate fondling Mutual masturbation Digital penetration Oral/genital contact Anal or vaginal intercourse Sexual exploitation Exposure to pornography Injuries to the genital/anal area Sexually transmitted diseases Pregnancy Bruises, scratches, burns or bite marks 	 Encouraging children/young people to become prostitutes Encouraging children to witness intercourse or pornographic acts Leaving a child in the care of a known sex offender Internet child pornography Self harm eg. suicide, self mutilation, substance misuse Bleeding from vagina or anus Pain in passing urine or faeces Persistent discharge 	behaviour of adult/ carer Physical signs on child/ young	 Abandonment or desertion Leaving alone Malnourishment, lack of food, inappropriate food or erratic feeding Lack of warmth Lack of adequate clothing Lack of protection or lack of supervision appropriate to child's age and developmental stage Persistent failure to attend school Delayed physical development: underweight and small of stature Hands and feet which are cold and puffy Chronic nappy rash 	 Leaving child alone to care for younger siblings Lack of appropriate stimulation Lack of protection from dangerous substances eg. fire, drugs, chemicals Lack of appropriate medical care Lack of secure attachment Persistently hungry Non-organic failure to thrive Impairment of health



Implications for practice - signs and symptoms of abuse should never be interpreted in isolation and must always be assessed in the context of the child's medical and social history, developmental stage and explanation given

Emergency Hormone Contraception Service Specification 2022 / 2023